Syndax Pharmaceuticals (SNDX) Financial Statements

916 Followers

Syndax Pharmaceuticals Financial Overview

Syndax Pharmaceuticals's market cap is currently $1.82B. The company's EPS TTM is $; its P/E ratio is -6.38; Syndax Pharmaceuticals is scheduled to report earnings on April 30, 2026, and the estimated EPS forecast is $-0.61. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	$ 172.35M	$ 23.68M	$ 0.00	$ 0.00	$ 139.71M
Gross Profit	$ 165.38M	$ 22.85M	$ 0.00	$ 0.00	$ 139.71M
Operating Income	$ -273.08M	$ -339.67M	$ -229.95M	$ -151.76M	$ 26.22M
EBITDA	$ -251.64M	$ -313.82M	$ -209.14M	$ -146.17M	$ 26.87M
Net Income	$ -285.42M	$ -318.76M	$ -209.36M	$ -149.34M	$ 24.93M
Balance Sheet
Cash & Short-Term Investments	$ 394.07M	$ 582.91M	$ 577.58M	$ 484.40M	$ 446.83M
Total Assets	$ 529.71M	$ 724.82M	$ 612.88M	$ 497.24M	$ 449.66M
Total Debt	$ 346.48M	$ 345.74M	$ 1.64M	$ 1.16M	$ 20.97M
Net Debt	$ 211.55M	$ 191.66M	$ -293.76M	$ -73.19M	$ -201.00M
Total Liabilities	$ 465.08M	$ 436.69M	$ 58.68M	$ 29.79M	$ 41.29M
Stockholders' Equity	$ 64.63M	$ 288.12M	$ 554.20M	$ 467.45M	$ 408.37M
Cash Flow
Free Cash Flow	$ -323.17M	$ -274.90M	$ -160.60M	$ -133.90M	$ 29.00M
Operating Cash Flow	$ -322.98M	$ -274.90M	$ -160.60M	$ -133.68M	$ 29.13M
Investing Cash Flow	$ 290.04M	$ -219.78M	$ 117.61M	$ -186.19M	$ -40.87M
Financing Cash Flow	$ 13.68M	$ 353.37M	$ 264.13M	$ 172.25M	$ 118.46M

Currency in USD

Syndax Pharmaceuticals Earnings and Revenue History

Income Statement >

Syndax Pharmaceuticals Debt to Assets

Balance Sheet >

Syndax Pharmaceuticals Cash Flow

Cash Flow >

Syndax Pharmaceuticals Forecast EPS vs Actual EPS

Currently, no data available

Please return soon. This page is being updated.

Earnings >